The renin system: Is direct renin inhibition different from blockade at the AT1 receptor or the ACE step?

Reviews in Cardiovascular Medicine

Volumn 8, Issue SUPPL. 2, 2007, Pages

  Hollenberg, Norman K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aliskiren; Angiotensin converting enzyme inhibitors; AT1 receptor blockers; Hypertension

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; COLLAGEN TYPE 1; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALKIREN; IMIDAZOLE DERIVATIVE; LISINOPRIL; LOSARTAN; MESSENGER RNA; NEUTRALIZING ANTIBODY; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRORENIN; RAMIPRIL; RENIN; RENIN INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; ZANKIREN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME INHIBITION; HORMONE INHIBITION; HUMAN; HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 33947228538     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Biron P, Boucher R, Deodhar SD, et al. Angiotensin. In: Page IH, McCubbin JW, eds. Renal Hypertension. Chicago: Yearbook Medical Publishers; 1962:68-98.
2. Skeggs LT, Kahn JR, Lentz KE, Shumway NP. Preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med. 1957;106:439-453.
3. Fisher NDL, Hollenberg NK. Is there a future for renin inhibitors? Expert Opin Investig Drugs. 2001;10:417-426.
4. Fisher NDL, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol. 2005;16:592-599.
5. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006;368:1449-1456.
6. Muller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol. 2006;1:221-228.
7. Azizi M. Renin inhibition. Curr Opin Nephrol Hypertens. 2006;15:S05-510.
8. Cheng H, Harris RC. Potential side effects of renin inhibitors-mechanisms based on comparison with other renin-angiotensin blockers. Expert Opin Drug Saf. 2006;5:631-641.
9. Azizi M, Web R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006;24:243-256.
10. 1 receptors. In: Epstein M, Brunner HR, eds. Angiotensin II Receptor Antagonists. Philadelphia, PA: Hanley & Belfus; 2001:190.
11. Sever PS, Poulter NR, Elliot WJ, et al. Blood pressure reduction is not the only determinant of outcome. Circulation. 2006;113:2754-2772; discussion 2773-2774.
12. Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in the tissues of intact humans: evidence from comparative pharmacological interruption of the renin system. Hypertension. 1998;32:387-392.
13. Campbell DJ. Bioactive angiotensin peptides other than angiotensin II. In: Epstein M, Brunner HR, eds. Angiotensin II Receptor Antagonists. Philadelphia, PA: Hanley & Belfus; 2001:9-27.
14. Skinner SL. The pathophysiology of prorenin. In: Ian J, Robertson S, Nicholls MG, eds. The Renin-Angiotensin System. New York: Gower; 1993:7.1-7.11.
15. Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;10:1417-1427.
16. Nguyen G, Danser AHJ. The (pro)renin receptor: therapeutic consequences. Expert Opin Investis Drugs. 2006;15:1131-1135.
17. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-β1 and matrix proteins through receptor-mediated, angiotensin III-independent mechanisms. Kidney Int. 2006;69:105-113.
18. Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension. 1998;32:387-392.
19. Fisher NDL, Allan DR, Gaboury CL, Hollenberg NK. Intrarenal angiotensin II formation in humans: evidence from renin inhibition. Hypertension. 1995;25:935-939.
20. Andersen NH, Mogensen CE. Dual blockade of the renin-angiotensin system in diabetic and nondiabetic kidney disease. Curr Hypertens Rep. 2004;6:369-376.
21. Hollenberg NK. Is there a pharmacologic basis for combination renin axis blockade? Kidney Int. 2005;68:2901-2903.
22. Hollenberg NK, Raij L. Angiotensin-converting enzyme inhibition and renal protection: an assessment of implications for therapy. Arch Intern Med. 1993;153:2426-2435.